Latest / Glaucoma, Vision & Longevity: Supplements & Science / Lowering Eye Pressure: The Lumigan vs Roclanda Showdown

Transcript

Lowering Eye Pressure: The Lumigan vs Roclanda Showdown · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: Lowering eye pressure, the Lumigan versus Roklanda Showdown.
• 0:04
  SPEAKER_00: Open angle glaucoma and ocular hypertension are conditions where intraocular pressure is higher than normal, threatening vision.
• 0:11
  SPEAKER_00: Eye drops that reduce IOP are the first line defense.
• 0:15
  SPEAKER_00: In this showdown, we compare Lumigan, brand of bimatoprost, and rockland, called rocklatan in the U.S., a fixed-dose combo of latanoprost plus netarsudal, explaining how each works, how well it lowers pressure, side effects, dosing, cost, and which patients might benefit most.
• 0:32
  SPEAKER_00: Mechanism of Action.
• 0:33
  SPEAKER_00: The two drops work differently.
• 0:35
  SPEAKER_00: Lumigan bimatoprost is a prostaglandin analog.
• 0:39
  SPEAKER_00: Prostaglandin analogs act mainly by increasing the drainage of fluid out of the eye, especially via the uvioscleral outflow pathway.
• 0:46
  SPEAKER_00: Bimatoprost is converted in the eye to a form that boosts outflow of aqueous humor, reducing pressure.
• 0:53
  SPEAKER_00: For example, laboratory studies show bimatoprost lowers resistance in the trabecular meshwork by about 26%.
• 1:00
  SPEAKER_00: Clinically, bimatoprost and other prostaglandins like latanopost share this main effect.
• 1:05
  SPEAKER_00: More fluid drain leads to lower IOP.
• 1:08
  SPEAKER_00: Roklandda, latanoprost plus netarseutal, combines two actions.
• 1:12
  SPEAKER_00: The latanoprost part is another prostaglandin, working like bimatoprost to improve outflow.
• 1:17
  SPEAKER_00: On top of that, netarseudal is a rokinase rock inhibitor, a different class.
• 1:23
  SPEAKER_00: Nitarseudal's unique action is to relax the eye's conventional drainage meshwork, trabecular meshwork, and lower the pressure needed to push fluid out.
• 1:32
  SPEAKER_00: It also has secondary effects.
• 1:35
  SPEAKER_00: It can reduce pressure in the episcleral veins and even slightly reduce fluid production.
• 1:40
  SPEAKER_00: In short, while both drugs share the prostaglandin mechanism, increasing uvioscleral drainage, netarsutal adds a tug at the trabecular outflow route and venous side of things.
• 1:51
  SPEAKER_00: Efficacy.
• 1:52
  SPEAKER_00: Clinical trials show both lumagan and the netarseudal latanoprost combo can dramatically lower IOP, but the combo generally drops pressure further than latanoprost alone, and thus more than a single prostaglandin alone.
• 2:05
  SPEAKER_00: Lumigan monotherapy typically reduces IOP by a large percentage.
• 2:10
  SPEAKER_00: In trials of bimatoprost 0.03%, average drops of about 6-8 mmH, roughly 25 to 35% from baseline were seen.
• 2:18
  SPEAKER_00: For example, one analysis noted an average reduction around 7.7 mmHg.
• 2:24
  SPEAKER_00: This means from a starting IOP in the mid-20s, many patients on lumagin drop into the high teens.
• 2:29
  SPEAKER_00: In fact, bimatoprost has consistently shown strong pressure lowering.
• 2:33
  SPEAKER_00: Multiple studies and meta-analyses found it often lowers IOP slightly more than other prostaglandins like latanoprost.
• 2:41
  SPEAKER_00: For Roklanda rochlatin, netarseudal plus latanoprost, phase 3 trials, the Mercury studies, found even bigger drops compared to each drug alone.
• 2:50
  SPEAKER_00: In those trials, adding netarseudal to latanoprost produced an extra 1.5 to 3 mmherazerin reduction in IOP beyond latanoprost alone.
• 2:59
  SPEAKER_00: In concrete terms, patients on the combination averaged IOPs around 15-16 mmG at follow-up, compared to about 17 to 18 mmHz on latanoprost alone.
• 3:10
  SPEAKER_00: Notably, at three months, one study reported 42% of patients on the combo hit a mean pressure 15 mmg, while only about 16 to 18% did so on latanoprost or netarseudal alone.
• 3:22
  SPEAKER_00: In pooled analyses, Roklanda patients had mean daytime IOP 15 to 16 mmHzg versus 17 to 18 mmHzgram on latanoprost alone.
• 3:32
  SPEAKER_00: There are no direct head-to-head trials comparing lumagan versus the netarsutal-latanoprost combo.
• 3:37
  SPEAKER_00: The recent Mercury 3 trial compared the combo to bimatoprost timolol rather than bimatoprost alone.
• 3:43
  SPEAKER_00: Thus we rely on separate data.
• 3:45
  SPEAKER_00: Prostaglandin drops like lumigan give a strong single-agent effect, while the fixed combo can add on extra pressure reduction for those needing it.
• 3:53
  SPEAKER_00: The combined drug is designed for patients not at target on a prostaglandin alone.
• 3:59
  SPEAKER_00: Side effects and tolerability.
• 4:01
  SPEAKER_00: Side effects of these drops are mostly well-known ocular reactions.
• 4:06
  SPEAKER_00: Prostaglandin analogues, Lumigan's bimatoprost and Roclanda's Latanoprost, commonly cause mild eye redness, conjunctival hyperemia, longer or thicker eyelashes, and gradual darkening of the iris color and surrounding skin.
• 4:20
  SPEAKER_00: These changes come from the drug's pharmacology.
• 4:23
  SPEAKER_00: For example, Lumigan's prescribing information notes pigmentation changes, iris, eyelid lashes, and eyelash growth.
• 4:30
  SPEAKER_00: In practice, redness on Lumigan 0.01% affects about 30% of patients.
• 4:36
  SPEAKER_00: A higher 0.03% dose had more.
• 4:40
  SPEAKER_00: Eyelash growth and iris darkening are not dangerous and can even be cosmetically welcome.
• 4:45
  SPEAKER_00: They gave rise to Latisse eyelash formulation.
• 4:48
  SPEAKER_00: However, the pigmentation changes tend to be permanent, and some patients dislike puffiness or deepening of the eye folds, sunken eyes seen with prostaglandins.
• 4:57
  SPEAKER_00: Overall, prostaglandin side effects are usually mild to moderate, but they lead many patients to notice their eyes look a bit different.
• 5:05
  SPEAKER_00: Nedarseudal, by contrast, has a distinctive side effect profile.
• 5:10
  SPEAKER_00: The most common issue is also redness, in fact, even higher than with prostaglandins.
• 5:15
  SPEAKER_00: Clinical data report redness in over 50% of netarseutal-treated eyes.
• 5:20
  SPEAKER_00: Nedarseudal can also cause conjunctival hemorrhages, tiny red blood spots on the white of the eye, and corneal verticillata, whirl-like deposits on the cornea, in up to 10 to 20% of patients.
• 5:33
  SPEAKER_00: For example, Repress's label notes Bosh 53% hyperemia and about 20% cornea deposits or hemorrhages.
• 5:40
  SPEAKER_00: In rock latin trials, about 59% of combo patients had some hyperemia, and 11% had conjunctival bleeding and 15% had corneal deposits.
• 5:49
  SPEAKER_00: Latanoprost's own side effects, modest pigment lash changes, can add to this but are relatively minor compared to the big difference in redness between netarseudal versus prostaglandin.
• 6:00
  SPEAKER_00: In summary, Lumigan's typical adverse effects, eye redness, hyperemia, very common, 31% on 0.01%, eyelash and eyelid changes, growth darkening, and possible eyelid fat loss, iris color darkening, permanent.
• 6:14
  SPEAKER_00: Roclanda's common adverse effects, netarseudalatinoprost, hyperemia redness, very common, subconjunctival hemorrhage, small at 11%, corneal verticillata deposits, choice 15%, eyelash or pigmentation changes from the latinoprost, generally milder than with bimatoprost.
• 6:36
  SPEAKER_00: These side effects affect tolerability.
• 6:39
  SPEAKER_00: In practice, up to 40 to 45% of patients on a prostaglandin drop report some adverse event, and redness is often the main complaint.
• 6:47
  SPEAKER_00: The higher redness rate with netarsidal combinations can be uncomfortable.
• 6:51
  SPEAKER_00: Many patients describe mild stinging or a bloodshot eye that typically fades over time.
• 6:57
  SPEAKER_00: Such effects do influence real-world use.
• 7:00
  SPEAKER_00: Patients bothered by redness or irritation may skip doses or switch drugs.
• 7:05
  SPEAKER_00: Interestingly, in the netarcidal vs.
• 7:07
  SPEAKER_00: Lahanopros studies, some reported the red eye of netarcidal tended to decrease after a month of nightly dosing.
• 7:14
  SPEAKER_00: Both drugs are usually given at bedtime in part to minimize noticing these effects during waking hours.
• 7:20
  SPEAKER_00: Dosing and convenience.
• 7:22
  SPEAKER_00: Both lumagin and rockland are simple once-daily drops, usually one drop in the affected eyes each evening.
• 7:28
  SPEAKER_00: Lumagumin 0.01 to 03% is instilled nightly, as is rocklatatin.
• 7:34
  SPEAKER_00: Netarsudal 0.2%, latanoprost 0.05%.
• 7:39
  SPEAKER_00: So neither requires multiple doses per day.
• 7:41
  SPEAKER_00: A convenience point.
• 7:42
  SPEAKER_00: Roklanda provides two active ingredients in one bottle.
• 7:45
  SPEAKER_00: If a patient needs both a prostaglandin and netarsudal, using the fixed combo means only one dropper instead of two separate bottles.
• 7:53
  SPEAKER_00: For example, someone already on Latanoprost who adds netarsudal could use rocklaton and simplify their regimen.
• 8:01
  SPEAKER_00: By contrast, if a patient on lumagin needs extra therapy, they would typically add a second bottle, another drug.
• 8:08
  SPEAKER_00: The single bottle combination can improve adherence for some patients by reducing the number of separate medications to juggle.
• 8:16
  SPEAKER_00: Cost, availability, and approval.
• 8:18
  SPEAKER_00: Lumagan, Bimatoprost, is a well-established medication.
• 8:22
  SPEAKER_00: In the U.S., it was originally approved in 2001 as.03% and later.01% and has parent patent expiration spun off generics.
• 8:32
  SPEAKER_00: Generic versions of Bimatoprost.pyro1% were approved around 2025.
• 8:37
  SPEAKER_00: In practice, generic Bimatoprost drops are now widely available, making this therapy relatively inexpensive with insurance or discount programs.
• 8:45
  SPEAKER_00: By contrast, the brand Lumagan Without Insurance can cost hundreds of dollars for a bottle, though coupons often reduce this.
• 8:52
  SPEAKER_00: Roklanda, Latanoprost Natarsudl is newer.
• 8:56
  SPEAKER_00: The European Medicines Agency, EMA, gave approval in January 2021.
• 9:01
  SPEAKER_00: It is marketed in the U.S.
• 9:02
  SPEAKER_00: as Rock Latin, FDA approval 2019.
• 9:05
  SPEAKER_00: As a brand name combination, it is pricier.
• 9:08
  SPEAKER_00: There are currently no generic versions of the Natarsudal Latanoprost combo.
• 9:12
  SPEAKER_00: Natarsudal itself is proprietary.
• 9:15
  SPEAKER_00: Without insurance, Rocklatan's cost is several hundred dollars for a month's supply.
• 9:20
  SPEAKER_00: Many insurance plans require patients to try simpler therapy first, for example, requiring failure of a prostaglandin drop before covering the combo.
• 9:29
  SPEAKER_00: Regional differences apply.
• 9:30
  SPEAKER_00: In Europe, Rockland would be covered by national health systems similarly to other secondline glaucoma meds.
• 9:37
  SPEAKER_00: Ideal patient profiles lumigan, bimataprost monotherapy, is often used as a first-choice eye drop for open-angle glaucoma or ocular hypertension because it's very effective and simple.
• 9:50
  SPEAKER_00: It suits a patient whose target IOP is modestly low and who tolerates prostaglandin side effects.
• 9:56
  SPEAKER_00: Many patients starting glaucoma therapy will see significant IOP reduction on lumagan alone.
• 10:03
  SPEAKER_00: It's also useful for long-term maintenance if the drop controls pressure without intolerable side effects.
• 10:09
  SPEAKER_00: The 0.01% formulation was specifically introduced to improve tolerability.
• 10:14
  SPEAKER_00: Studies showed it maintains similar efficacy with less redness, improving adherence.
• 10:20
  SPEAKER_00: Roklanda rockladen is typically used for patients who need more lowering than a prostaglandin alone can provide.
• 10:27
  SPEAKER_00: For example, someone already on letanoprost or bimatoprost, whose pressure remains above target, or someone starting therapy at a very high IOP, might benefit from the extra kick of adding netarsudal.
• 10:39
  SPEAKER_00: The combination is specifically indicated for patients in whom monotherapy, either a prostaglandin or netarseutal, does not sufficiently reduce IOP.
• 10:48
  SPEAKER_00: In practice, Roklanda might be favored for patients who need an extra 2 to 3 mm drop or a higher chance to reach mid-teens intraocular pressure, and for those who can accept a higher chance of redness.
• 11:01
  SPEAKER_00: In summary, both drugs are authoritative glaucoma therapies, but fit slightly different needs.
• 11:07
  SPEAKER_00: Lumigan is a proven first-line prostaglandin drop, simple, once daily, with well-known side effects.
• 11:14
  SPEAKER_00: Roklanda is a newer combination option for more aggressive lowering or as a next step if a prostaglandin alone isn't enough.
• 11:21
  SPEAKER_00: Deciding between them depends on how low the eye pressure must go, previous response to medications, side effect sensitivity, and cost insurance factors.
• 11:31
  SPEAKER_00: Disclaimer: This article is for educational purposes only and is not intended as medical advice.
• 11:37
  SPEAKER_00: Patients should consult a healthcare provider for personalized treatment decisions.
• 11:42
  SPEAKER_00: All links to sources are available in the text version of this article.
• 11:46
  SPEAKER_00: You can find the full article at VisualFieldTest.com.
• 11:50
  SPEAKER_00: Thanks for listening.
• 11:52
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.